查看文章

Background

Therapeutic options for Crohn’s disease are growing, making the choice of first-line therapy relevant. Both adalimumab and ustekinumab are effective in moderate-to-severe Crohn’s disease. The Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year trial suggested no difference in clinical or endoscopic remission at week 52 in biological-naive Crohn’s disease patients. We explored if results withstand in the real world.

Methods

We included bio-naive Crohn’s disease patients starting adalimumab or ustekinumab between 2017 and 2020. Patients had endoscopy-proven moderate-to-severe disease [Simple Endoscopic Score for Crohn’s disease (SES-CD)≥ 3]. Clinical remission was defined as Harvey Bradshaw Index (HBI)< 5 or physician global assessment. Endoscopic remission (SES-CD< 3) and improvement (≥ 50% reduction in SES-CD from baseline) were assessed at W26-52 …